RCS - ReNeuron Group plc - Initiation of research by Allenby Capital

ReNeuronAnnouncement

29/04/2021 07:05

RNS Number : 9643W
  
ReNeuron Group plc
  
29 April 2021
  
 

ReNeuron Group plc
("ReNeuron" or the "Company")
 
Initiation of research by Allenby Capital
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the initiation of research by Allenby Capital Limited, the Company's joint broker.
 
The research is available to view on the ReNeuron website here: http://www.reneuron.com/investors/analyst-research-and-presentations/
 
Contacts:
 




ReNeuron


www.reneuron.com/investors




Olav Hellebø, Chief Executive Officer


Via Walbrook PR




Michael Hunt, Chief Financial Officer


 




 


 




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Ben Maddison, Stewart Wallace


+44 (0)20 7710 7600
 




 


 




Allenby Capital Limited (Joint Broker)
James Reeve/George Payne (Corporate Finance)
Tim Sohal (Sales & Corporate Broking)


+44 (0)20 3328 5656



 
 



Walbrook PR (Media & Investor Relations) 


+44 (0)20 7933 8780 or reneuron@walbrookpr.com




Paul McManus, Alice Woodings


+44 (0)7980 541 893 / +44 (0)7407 804 654




 
About ReNeuron 
 
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.  
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com
  
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAEASLPALDFEFA